Domov › Folikulárny lymfóm › Massachusetts › Boston
Klinické štúdie Folikulárny lymfóm v meste Boston, MA
17 štúdií pre Folikulárny lymfóm hľadá účastníkov v zariadeniach v meste Boston a okolí (do cca 30 míľ). Otvorte štúdiu a zistite, kto sa môže zapojiť a ako kontaktovať tím.
Oficiálny text štúdie (anglicky)
Hľadáte účastníkov do štúdie? Zvýraznite ju na začiatku tejto stránky – $99 na 30 dní →
A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies
Prebieha náborFáza 1/2
- Dana Farber Cancer Institute, Boston
Testing Addition of an Anti-cancer Drug, Vorasidenib to Temozolomide, After Radiation for Advanced Brain Cancer
Prebieha náborFáza 3
- Tufts Medical Center, Boston
- Massachusetts General Hospital Cancer Center, Boston
- Dana-Farber Cancer Institute, Boston
Epco, Zanu, Ritux for R/R FL or MZL
Prebieha náborFáza 2
- Dana-Farber Cancer Institute, Boston
A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )
Prebieha náborFáza 1
- Massachusetts General Hospital, Boston
- Dana-Farber Cancer Institute, Boston
A Study of LY4584180 in Adult Participants With Previously Treated Blood Cancers
Prebieha náborFáza 1
- Massachusetts General Hospital, Boston
- Dana-Farber Cancer Institute, Boston
A Study of Surovatamig (AZD0486) Plus Rituximab in Previously Untreated Follicular Lymphoma Patients
Prebieha náborFáza 3
- Research Site, Boston
- Research Site, Boston
NEO100 and High-Grade Meningioma
Prebieha náborFáza 2
- Tufts Medical Center, Boston
A Trial to Learn if Odronextamab is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Different Types of Chemotherapy for Adult Participants With Previously Untreated Follicular Lymphoma
Prebieha náborFáza 3
- Beth Israel Deaconess Medical Center, Boston
SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance)
Prebieha náborFáza 3
- Massachusetts General Hospital, Boston
- Dana-Farber Cancer Institute, Boston
Epcoritamab and Rituximab for First-line Follicular Lymphoma
Prebieha náborFáza 2
- Beth Israel Deaconess Medical Center, Boston
- Dana-Farber Cancer Institute, Boston
A Study to Compare the Efficacy and Safety of Golcadomide in Combination With Rituximab (Golca + R) vs Investigator's Choice in Participants With Relapsed/Refractory Follicular Lymphoma Who Have Received at Least 1 Prior Line of Systemic Therapy (GOLSEEK-4)
Prebieha náborFáza 3
- Local Institution - 0145, Boston
- Local Institution - 0244, Boston
- Local Institution - 0247, Boston
CD79b-19 CAR T Cells in Non-Hodgkin Lymphoma
Prebieha náborFáza 1
- Massachusetts General Hospital, Boston
Odronextamab in Low Tumor Volume Advanced FL
Prebieha náborFáza 2
- Beth Israel Deaconess Medical Center, Boston
Epcoritamab in Patients With Follicular Lymphoma Not Accomplishing a CR With Upfront Chemoimmunotherapy
Prebieha náborFáza 2
- Beth Israel Deaconess Medical Center, Boston
Study of SGR-1505 in Mature B-Cell Neoplasms
Prebieha náborFáza 1
- Beth Israel Deaconess Medical Center, Boston
A Novel Vaccine (EO2463) as Monotherapy and in Combination, for Treatment of Patients With Indolent Non-Hodgkin Lymphoma
Prebieha náborFáza 1/2
- Dana Farber Cancer Institute, Boston
Emapalumab Prevention of CAR-T Cell Associated Toxicities
Prebieha náborFáza 2
- Massachusetts General Hospital, Boston
- Dana-Farber Cancer Institute, Boston
Štúdie Folikulárny lymfóm v iných mestách
- New York City, NY24 štúdií
- Milwaukee, WI19 štúdií
- Nashville, TN18 štúdií
- Houston, TX18 štúdií
- Baldwin Park, CA16 štúdií
- Seattle, WA15 štúdií
- Durham, NC15 štúdií
- Salt Lake City, UT13 štúdií
- Columbus, OH13 štúdií
- Chicago, IL12 štúdií
- San Antonio, TX12 štúdií
- Philadelphia, PA12 štúdií
Iné štúdie v Boston
- Rakovina prsníka112 štúdií
- Nemalobunkový karcinóm pľúc90 štúdií
- Rakovina (všetky typy)85 štúdií
- Metastatická rakovina63 štúdií
- Kolorektálny karcinóm63 štúdií
- Rakovina pľúc62 štúdií
- Rakovina vaječníkov61 štúdií
- Rakovina prostaty59 štúdií
- Depresia52 štúdií
- Rakovina endometria50 štúdií
- Srdcové zlyhanie44 štúdií
- Akútna myeloidná leukémia44 štúdií
Z ClinicalTrials.gov, dáta načítané 6. 10. 2026. Každá štúdia má vlastné kritériá oprávnenosti; tím štúdie rozhoduje o účasti.